Serious & Notifiable Infections — MCQs
On this page
What is the primary reason for adding pyridoxine (vitamin B6) supplementation to tuberculosis treatment regimens containing isoniazid?
A 45-year-old man from Pakistan completes 6 months of treatment for fully drug-sensitive pulmonary tuberculosis with the standard four-drug regimen (2 months of rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampicin and isoniazid). He was adherent to therapy throughout. His chest X-ray at completion shows improvement with some residual fibrotic changes but no cavitation. Sputum smears and cultures at treatment completion are negative. What is the most appropriate ongoing management?
A 28-year-old woman presents to the emergency department with an 8-hour history of severe headache, fever, photophobia, and vomiting. She has a non-blanching purpuric rash on her legs. Glasgow Coma Scale is 14 (E4 V4 M6). Blood pressure is 95/60 mmHg, heart rate 118/min, temperature 39.1°C. What is the most appropriate immediate management?
A 52-year-old man is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. Culture and full drug susceptibility testing are pending. He has no history of previous TB treatment and has not lived in a high MDR-TB prevalence area. What is the most appropriate initial management while awaiting full susceptibility results?
A 33-year-old woman from Romania presents with a 3-month history of progressive headache, confusion, and personality change. She has HIV infection with a CD4 count of 85 cells/mm³ and is not on antiretroviral therapy. MRI brain shows multiple ring-enhancing lesions with surrounding oedema in the basal ganglia and cerebral cortex. Lumbar puncture shows: opening pressure 19 cmH2O, protein 0.8 g/L, glucose 3.1 mmol/L (plasma 5.4 mmol/L), white cells 45/mm³ (80% lymphocytes). CSF cryptococcal antigen is negative. What is the most appropriate initial empirical antimicrobial therapy?
According to UK notification requirements, which of the following conditions must be notified to the local health protection team within 24 hours of clinical suspicion, before laboratory confirmation?
A 42-year-old man with pulmonary tuberculosis has been on standard four-drug therapy for 8 weeks. His sputum culture from diagnosis has now grown Mycobacterium tuberculosis fully sensitive to all first-line agents. Sputum smears at 8 weeks remain positive. He reports good adherence and directly observed therapy confirms this. Liver function tests and renal function are normal. What is the most appropriate next step in management?
A 7-year-old girl presents with a 2-month history of low-grade fever, weight loss, and progressive drowsiness. Her parents recently immigrated from India. On examination, she has neck stiffness and bilateral papilloedema. Lumbar puncture shows: opening pressure 28 cmH2O, CSF protein 2.4 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (90% lymphocytes). Ziehl-Neelsen stain is negative. Which organism is most likely to be identified on CSF culture?
A 49-year-old man presents with a 7-week history of cough, weight loss, and night sweats. He is a recent migrant from Pakistan. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum microscopy shows acid-fast bacilli. HIV test is negative. He is commenced on rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 2 g, and ethambutol 1200 mg daily. Three days later he develops severe nausea, vomiting, right upper quadrant pain, and jaundice. Blood tests show: bilirubin 145 μmol/L, ALT 856 U/L, ALP 198 U/L, albumin 38 g/L. Which is the most appropriate immediate management?
Which one of the following clinical features in a patient with bacterial meningitis carries the highest risk of poor neurological outcome?
Serious & Notifiable Infections UK Medical PG Practice Questions and MCQs
Question 111: What is the primary reason for adding pyridoxine (vitamin B6) supplementation to tuberculosis treatment regimens containing isoniazid?
- A. To prevent peripheral neuropathy caused by isoniazid (Correct Answer)
- B. To enhance the bactericidal activity of isoniazid
- C. To reduce the risk of hepatotoxicity from rifampicin
- D. To prevent optic neuritis caused by ethambutol
- E. To improve absorption of anti-tuberculous medications
Explanation: ***To prevent peripheral neuropathy caused by isoniazid***- **Isoniazid** interferes with the metabolism of **pyridoxine** (vitamin B6) by inhibiting its conversion to the active form, **pyridoxal phosphate**, which is crucial for nerve function.- This interference leads to a deficiency, causing **peripheral neuropathy**, and pyridoxine supplementation is essential to prevent this dose-limiting neurotoxicity.*To enhance the bactericidal activity of isoniazid*- **Pyridoxine** supplementation is solely for mitigating **isoniazid-induced toxicity** and does not directly enhance the **bactericidal activity** or efficacy of the drug.- The mechanism of action of **isoniazid** against *Mycobacterium tuberculosis* is independent of vitamin B6 levels.*To reduce the risk of hepatotoxicity from rifampicin*- **Hepatotoxicity** is a significant side effect of both **rifampicin** and isoniazid, but **pyridoxine** does not offer protection against liver damage.- Management of drug-induced hepatotoxicity primarily involves monitoring liver enzymes and adjusting drug regimens, not vitamin B6 supplementation.*To prevent optic neuritis caused by ethambutol*- **Optic neuritis** is a well-known adverse effect specifically associated with **ethambutol** treatment, causing visual disturbances.- **Pyridoxine** has no known role in preventing or treating **ethambutol-induced optic neuropathy**.*To improve absorption of anti-tuberculous medications*- **Pyridoxine** supplementation does not influence the **absorption**, **bioavailability**, or **pharmacokinetics** of any anti-tuberculosis medications.- Its role is specific to counteracting the **neurotoxic side effect** of isoniazid, not to improve drug delivery.
Question 112: A 45-year-old man from Pakistan completes 6 months of treatment for fully drug-sensitive pulmonary tuberculosis with the standard four-drug regimen (2 months of rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampicin and isoniazid). He was adherent to therapy throughout. His chest X-ray at completion shows improvement with some residual fibrotic changes but no cavitation. Sputum smears and cultures at treatment completion are negative. What is the most appropriate ongoing management?
- A. Continue rifampicin and isoniazid for a further 3 months
- B. Clinical and radiological review at 12 months post-treatment (Correct Answer)
- C. Monthly sputum cultures for 6 months
- D. Start prophylactic isoniazid for 6 months
- E. No further follow-up required
Explanation: ***Clinical and radiological review at 12 months post-treatment***- For patients completing a standard 6-month regimen for **drug-sensitive tuberculosis** with negative end-of-treatment cultures, guidelines recommend a follow-up review at **12 months** to monitor for relapse.- This follow-up ensures the identification of the **2-3% of patients** who may experience recurrence despite successful initial therapy and documented adherence.*Continue rifampicin and isoniazid for a further 3 months*- Extending treatment to **9 months** is generally reserved for patients with **cavitary disease** and positive cultures at 2 months, which is not the case here.- The patient has already completed the standard **curative phase** for fully drug-sensitive TB with favorable clinical and microbiological responses.*Monthly sputum cultures for 6 months*- Routine **microbiological monitoring** after the completion of treatment is not indicated if the end-of-treatment sputum smears and cultures are negative.- Serial cultures offer low diagnostic yield in an **asymptomatic patient** with negative results at the time of discharge from care.*Start prophylactic isoniazid for 6 months*- **Isoniazid monotherapy** is used for latent TB infection, not for patients who have just successfully completed a full **combination therapy** for active disease.- There is no clinical benefit to adding **prophylaxis** after the intensive and continuation phases have sterilized the active lesions.*No further follow-up required*- While the response is excellent, complete discharge without any follow-up is inappropriate due to the small but significant risk of **relapse** within the first year.- Patients must still be educated on **red-flag symptoms** like fever or weight loss and undergo a scheduled final assessment to confirm sustained cure.
Question 113: A 28-year-old woman presents to the emergency department with an 8-hour history of severe headache, fever, photophobia, and vomiting. She has a non-blanching purpuric rash on her legs. Glasgow Coma Scale is 14 (E4 V4 M6). Blood pressure is 95/60 mmHg, heart rate 118/min, temperature 39.1°C. What is the most appropriate immediate management?
- A. Immediate CT head followed by lumbar puncture and antibiotics
- B. Blood cultures, then immediate lumbar puncture, followed by antibiotics
- C. Immediate IV ceftriaxone and supportive care without lumbar puncture (Correct Answer)
- D. Blood cultures, IV ceftriaxone, then lumbar puncture after CT head
- E. IV benzylpenicillin, blood cultures, and immediate lumbar puncture
Explanation: ***Immediate IV ceftriaxone and supportive care without lumbar puncture***- The presence of **fever**, **meningeal signs** (headache, photophobia, vomiting), **reduced GCS (14)**, and a **non-blanching purpuric rash** in a hemodynamically unstable patient (BP 95/60, HR 118) is highly indicative of **meningococcal septicaemia**.- In such critically ill patients with suspected **meningococcal disease**, immediate administration of **intravenous broad-spectrum antibiotics** (like ceftriaxone) is life-saving, and **lumbar puncture is contraindicated** or significantly delayed due to the risk of herniation and treatment delay.*Immediate CT head followed by lumbar puncture and antibiotics*- Performing an **immediate CT head** unnecessarily delays the administration of crucial, life-saving **antibiotics** in a patient with clinical signs of **sepsis** and suspected bacterial meningitis.- **Lumbar puncture** should not be performed immediately in a patient with **reduced GCS** and signs of shock, as it poses risks and delays the primary treatment of antibiotics.*Blood cultures, then immediate lumbar puncture, followed by antibiotics*- While **blood cultures** are important for diagnosis, they should not delay the **immediate administration of empirical intravenous antibiotics** in a patient with suspected **meningococcal sepsis**.- **Immediate lumbar puncture** is contraindicated and dangerous in this patient due to **reduced GCS (14)** and signs of **shock**, increasing the risk of cerebral herniation.*Blood cultures, IV ceftriaxone, then lumbar puncture after CT head*- Although giving **IV ceftriaxone** is correct, delaying it for **blood cultures** is less ideal than immediate administration, and mandating a **CT head** before **lumbar puncture** still introduces dangerous delays in antibiotic initiation for severe sepsis.- In cases of severe **meningococcal septicaemia** with instability, diagnosis is primarily clinical and confirmed by **blood cultures** and **PCR**, often precluding the need for a lumbar puncture.*IV benzylpenicillin, blood cultures, and immediate lumbar puncture*- While **benzylpenicillin** is an option, **ceftriaxone** is generally the preferred first-line **empiric antibiotic** for suspected bacterial meningitis in a hospital setting due to its broader spectrum and excellent CNS penetration.- **Immediate lumbar puncture** is unequivocally contraindicated in this patient due to **hemodynamic compromise** and **reduced GCS**, as it can exacerbate clinical instability and delay critical treatment.
Question 114: A 52-year-old man is diagnosed with smear-positive pulmonary tuberculosis. Molecular testing (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. Culture and full drug susceptibility testing are pending. He has no history of previous TB treatment and has not lived in a high MDR-TB prevalence area. What is the most appropriate initial management while awaiting full susceptibility results?
- A. Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin (Correct Answer)
- B. Start standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol
- C. Wait for full culture and susceptibility results before starting treatment
- D. Start isoniazid, rifampicin, pyrazinamide, ethambutol, and moxifloxacin
- E. Start bedaquiline, linezolid, and cycloserine
Explanation: ***Start isoniazid, pyrazinamide, ethambutol, and moxifloxacin*** - The detection of **rifampicin resistance** by GeneXpert is a critical finding, strongly indicating **Multidrug-Resistant TB (MDR-TB)**; thus, treatment must be modified immediately to include a **fluoroquinolone** like moxifloxacin. - **Isoniazid** is included empirically because some rifampicin-resistant strains remain sensitive to it, providing a robust initial regimen and contributing to preventing further drug resistance. *Start standard four-drug therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol* - Continuing **rifampicin** when molecular testing has confirmed resistance is inappropriate as it renders the drug ineffective, leading to **treatment failure** and sustained infectivity. - Standard therapy is inadequate for **MDR-TB** and would permit the development of additional resistance to the remaining first-line drugs. *Wait for full culture and susceptibility results before starting treatment* - The patient is **smear-positive**, indicating high infectiousness, and delaying treatment poses a significant **public health risk** for community transmission. - Full culture and susceptibility results can take several weeks, and immediate empirical treatment based on rapid molecular results is vital to prevent clinical deterioration and reduce infectivity. *Start isoniazid, rifampicin, pyrazinamide, ethambutol, and moxifloxacin* - Including **rifampicin** in the regimen when **rifampicin resistance** has been detected by **GeneXpert MTB/RIF** is clinically unsound and offers no therapeutic benefit, while potentially increasing drug toxicity. - Effective management for suspected MDR-TB relies on assembling at least four effective drugs to which the strain is likely **susceptible**, not retaining ineffective agents. *Start bedaquiline, linezolid, and cycloserine* - Initiating newer or potent second-line agents like **bedaquiline** is typically reserved for confirmed MDR-TB or extensively drug-resistant (XDR-TB), often following a **multidisciplinary team (MDT) review**. - These drugs generally carry higher **toxicity** and costs, making them secondary options to an established empirical MDR regimen while awaiting comprehensive phenotypic results.
Question 115: A 33-year-old woman from Romania presents with a 3-month history of progressive headache, confusion, and personality change. She has HIV infection with a CD4 count of 85 cells/mm³ and is not on antiretroviral therapy. MRI brain shows multiple ring-enhancing lesions with surrounding oedema in the basal ganglia and cerebral cortex. Lumbar puncture shows: opening pressure 19 cmH2O, protein 0.8 g/L, glucose 3.1 mmol/L (plasma 5.4 mmol/L), white cells 45/mm³ (80% lymphocytes). CSF cryptococcal antigen is negative. What is the most appropriate initial empirical antimicrobial therapy?
- A. Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone
- B. Ceftriaxone and aciclovir
- C. Pyrimethamine, sulfadiazine, and folinic acid (Correct Answer)
- D. Liposomal amphotericin B and flucytosine
- E. Co-trimoxazole and prednisolone
Explanation: ***Pyrimethamine, sulfadiazine, and folinic acid*** - In a patient with advanced **HIV (CD4 <100)** presenting with a subacute onset of neurological symptoms and **multiple ring-enhancing lesions** in the basal ganglia, **Cerebral Toxoplasmosis** is the most likely diagnosis. - This combination is the gold standard empirical therapy for active toxoplasmosis, with **folinic acid** added to prevent bone marrow suppression caused by **pyrimethamine**. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and dexamethasone* - This is the standard treatment for **Tuberculous meningitis**. While tuberculomas can cause ring-enhancing lesions, the CSF glucose is typically much lower, and the basal ganglia involvement is more characteristic of Toxoplasmosis in this CD4 count. - The progressive headache, confusion, and personality change over 3 months are less specific for acute TB meningitis, and Toxoplasmosis is statistically more common in this specific clinical and immunological setting. *Ceftriaxone and aciclovir* - This regimen targets **bacterial meningitis** (ceftriaxone) and **herpes simplex encephalitis** (aciclovir). - The subacute presentation, **multiple ring-enhancing lesions**, and lymphocytic pleocytosis with only mildly decreased CSF glucose are not typical for acute bacterial meningitis or HSE, which often has temporal lobe involvement. *Liposomal amphotericin B and flucytosine* - This is the induction treatment for **Cryptococcal meningitis**. - The **negative CSF cryptococcal antigen** explicitly rules out cryptococcal infection as the cause of the patient's symptoms. *Co-trimoxazole and prednisolone* - **Co-trimoxazole** can be used as an alternative or for prophylaxis of toxoplasmosis, but **pyrimethamine and sulfadiazine** are generally considered the first-line empirical therapy for active CNS toxoplasmosis due to superior efficacy. - Prednisolone may be considered for significant mass effect, but it is not the primary antimicrobial agent, and **co-trimoxazole** is not the preferred initial empirical treatment over the gold standard regimen.
Question 116: According to UK notification requirements, which of the following conditions must be notified to the local health protection team within 24 hours of clinical suspicion, before laboratory confirmation?
- A. Pulmonary tuberculosis
- B. Meningococcal septicaemia (Correct Answer)
- C. Latent tuberculosis infection
- D. Aseptic meningitis
- E. Extrapulmonary tuberculosis without central nervous system involvement
Explanation: ***Meningococcal septicaemia***- Under the **Health Protection Regulations 2010**, meningococcal disease must be notified as soon as it is clinically suspected to allow for immediate **chemoprophylaxis** of close contacts.- It is classified as an **urgent notification** because of its high mortality rate and potential for rapid spread, requiring notification often by telephone within **24 hours**.*Pulmonary tuberculosis*- While a **notifiable disease**, it generally requires notification within **three working days** after a diagnosis is confirmed or strongly suspected.- It does not carry the same level of immediate public health emergency as **invasive meningococcal disease** and does not require a 24-hour notification on raw clinical suspicion alone.*Latent tuberculosis infection*- This condition represents an **asymptomatic state** where the bacteria are persistent but not causing active disease; it is **not a notifiable condition** in the UK.- Reporting is restricted to **active tuberculosis** cases that pose a current risk of transmission to others.*Aseptic meningitis*- Typical **viral (aseptic) meningitis** is not specifically listed as a notifiable disease unless it is caused by a specific pathogen that is itself notifiable, such as **mumps** or **measles**.- Only **acute meningitis** (typically bacterial) is listed for urgent notification due to the high risk of clusters and severe outcomes.*Extrapulmonary tuberculosis without central nervous system involvement*- Similar to pulmonary TB, this is notifiable but falls under the standard **three-day reporting** period rather than the urgent clinical suspicion category.- Notification usually awaits more definitive **diagnostic investigations** rather than initial clinical suspicion at the point of presentation.
Question 117: A 42-year-old man with pulmonary tuberculosis has been on standard four-drug therapy for 8 weeks. His sputum culture from diagnosis has now grown Mycobacterium tuberculosis fully sensitive to all first-line agents. Sputum smears at 8 weeks remain positive. He reports good adherence and directly observed therapy confirms this. Liver function tests and renal function are normal. What is the most appropriate next step in management?
- A. Continue current therapy and repeat sputum smears at 12 weeks (Correct Answer)
- B. Add a fluoroquinolone to the current regimen
- C. Switch to second-line anti-tuberculous therapy
- D. Increase the dose of rifampicin
- E. Perform therapeutic drug monitoring
Explanation: ***Continue current therapy and repeat sputum smears at 12 weeks*** - Sputum smear conversion is expected by **8 weeks (2 months)** in most patients with drug-sensitive TB, but a delay is not uncommon and does not automatically indicate treatment failure or drug resistance, especially with confirmed **adherence**. - Standard guidelines recommend continuing the current regimen and reassessing sputum microscopy at the **end of 3 months (12 weeks)** before considering further investigations or changes to therapy. *Add a fluoroquinolone to the current regimen* - Adding a single new drug to a failing or slowly responding regimen in active TB can rapidly lead to the development of **acquired drug resistance** to the newly added drug. - Since the organism is confirmed **fully sensitive** to first-line agents, there is no clinical indication for the empirical addition of a second-line drug at this stage. *Switch to second-line anti-tuberculous therapy* - Switching to **second-line anti-tuberculous therapy** is reserved for confirmed cases of **multidrug-resistant TB (MDR-TB)**, extensively drug-resistant TB (XDR-TB), or severe intolerance to first-line agents. - In this scenario, the *M. tuberculosis* isolate is **fully sensitive** to all first-line agents, and there is no evidence of intolerance, making a premature switch inappropriate. *Increase the dose of rifampicin* - Increasing the dose of **rifampicin** beyond standard weight-based recommendations is generally not advised unless there are specific pharmacokinetic reasons, such as confirmed **malabsorption** or drug-drug interactions. - Empirically increasing the dose without evidence of sub-therapeutic levels or malabsorption could increase the risk of dose-dependent adverse effects, particularly **hepatotoxicity**. *Perform therapeutic drug monitoring* - **Therapeutic drug monitoring (TDM)** is typically considered in patients with underlying comorbidities that affect drug pharmacokinetics, such as **HIV co-infection**, diabetes, renal/hepatic impairment, or suspected malabsorption. - Given that the patient has **normal liver and renal function** and confirmed **good adherence** through directly observed therapy (DOT), TDM is not the immediate priority over continued clinical and microbiological observation.
Question 118: A 7-year-old girl presents with a 2-month history of low-grade fever, weight loss, and progressive drowsiness. Her parents recently immigrated from India. On examination, she has neck stiffness and bilateral papilloedema. Lumbar puncture shows: opening pressure 28 cmH2O, CSF protein 2.4 g/L, glucose 1.8 mmol/L (plasma glucose 5.2 mmol/L), white cells 180/mm³ (90% lymphocytes). Ziehl-Neelsen stain is negative. Which organism is most likely to be identified on CSF culture?
- A. Mycobacterium tuberculosis (Correct Answer)
- B. Streptococcus pneumoniae
- C. Neisseria meningitidis
- D. Listeria monocytogenes
- E. Cryptococcus neoformans
Explanation: ***Mycobacterium tuberculosis***- The subacute presentation of **low-grade fever**, **weight loss**, and **progressive drowsiness** over 2 months, especially in a child whose parents recently immigrated from **India** (a TB-endemic area), is highly characteristic of **Tuberculous Meningitis (TBM)**.- The CSF findings of **lymphocytic pleocytosis** (90% lymphocytes), **very high protein** (2.4 g/L), **very low glucose** (1.8 mmol/L, with a plasma glucose of 5.2 mmol/L), and **raised opening pressure** (28 cmH2O) with **papilloedema** are the hallmarks of TBM, even if the Ziehl-Neelsen stain is negative due to low bacillary load.*Streptococcus pneumoniae*- This typically presents with an **acute onset** of symptoms (hours to days), including high fever, severe headache, and rapid deterioration, not a 2-month history.- CSF analysis would predominantly show a **neutrophilic pleocytosis** (high percentage of neutrophils) rather than the lymphocytic predominance seen here.*Neisseria meningitidis*- This also causes an **acute bacterial meningitis**, often associated with a characteristic **non-blanching purpuric rash** and rapid progression to sepsis.- Similar to S. pneumoniae, its CSF profile would typically demonstrate a prominent **neutrophilic pleocytosis**.*Listeria monocytogenes*- This organism commonly affects **neonates**, the **elderly**, or **immunocompromised** individuals; it's less common as a primary cause in an immunocompetent 7-year-old with this specific chronic presentation.- While it can cause a mixed or lymphocytic CSF picture, the strong epidemiological link to a TB-endemic area and the chronic systemic symptoms make **tuberculosis** a much more likely diagnosis.*Cryptococcus neoformans*- This is primarily an opportunistic pathogen, most commonly causing meningitis in **immunocompromised** patients, particularly those with HIV/AIDS.- Although it can present subacutely with lymphocytic pleocytosis and low glucose, the absence of overt immunocompromise and the strong epidemiological history point away from cryptococcal infection in favor of **TBM**.
Question 119: A 49-year-old man presents with a 7-week history of cough, weight loss, and night sweats. He is a recent migrant from Pakistan. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum microscopy shows acid-fast bacilli. HIV test is negative. He is commenced on rifampicin 600 mg, isoniazid 300 mg, pyrazinamide 2 g, and ethambutol 1200 mg daily. Three days later he develops severe nausea, vomiting, right upper quadrant pain, and jaundice. Blood tests show: bilirubin 145 μmol/L, ALT 856 U/L, ALP 198 U/L, albumin 38 g/L. Which is the most appropriate immediate management?
- A. Stop all anti-tuberculous medications and monitor liver function daily until ALT <100 U/L, then reintroduce drugs sequentially starting with rifampicin (Correct Answer)
- B. Stop pyrazinamide only, continue other three drugs, and monitor liver function
- C. Stop rifampicin, isoniazid, and pyrazinamide; continue ethambutol; start streptomycin and levofloxacin
- D. Continue all four drugs but reduce doses by 50% and add ursodeoxycholic acid for hepatoprotection
- E. Stop all anti-tuberculous medications; start steroids to treat drug-induced hepatitis
Explanation: ***Stop all anti-tuberculous medications and monitor liver function daily until ALT <100 U/L, then reintroduce drugs sequentially starting with rifampicin*** - The patient presents with severe **drug-induced liver injury (DILI)**, indicated by **jaundice** (bilirubin 145 μmol/L) and a significantly elevated **ALT (856 U/L)**, necessitating the immediate cessation of all potentially hepatotoxic anti-tuberculous drugs. - The standard management for severe DILI involves withdrawing all suspected drugs and monitoring liver function until it significantly improves, followed by **sequential reintroduction** of drugs, often starting with **rifampicin** under close observation. *Stop pyrazinamide only, continue other three drugs, and monitor liver function* - While **pyrazinamide** is highly hepatotoxic, **isoniazid** and **rifampicin** are also significant contributors to DILI, and continuing them in the presence of acute liver injury carries a high risk of **fulminant hepatic failure**. - When severe, symptomatic DILI occurs, the general guideline is to stop all potentially hepatotoxic drugs to prevent further liver damage. *Stop rifampicin, isoniazid, and pyrazinamide; continue ethambutol; start streptomycin and levofloxacin* - This approach involves discontinuing the main hepatotoxic drugs but immediately introducing a more complex alternative regimen with **streptomycin** and **levofloxacin**. - The immediate priority in severe DILI is to remove all offending agents and allow the liver to recover, rather than immediately initiating a new multi-drug regimen, which should be done once liver function stabilizes. *Continue all four drugs but reduce doses by 50% and add ursodeoxycholic acid for hepatoprotection* - Continuing all four anti-tuberculous drugs, even at reduced doses, during acute severe DILI is highly dangerous and risks progression to **acute liver failure**. - Reducing doses increases the risk of developing **drug-resistant tuberculosis** due to subtherapeutic drug levels, and **ursodeoxycholic acid** lacks sufficient evidence to protect against severe DILI from TB drugs. *Stop all anti-tuberculous medications; start steroids to treat drug-induced hepatitis* - While steroids might be considered in very specific, severe autoimmune-like DILI cases, they are not standard treatment for typical **drug-induced hepatitis** and can be detrimental. - Administering **corticosteroids** in a patient with active **pulmonary tuberculosis** can lead to immunosuppression, potentially worsening the underlying infection or causing dissemination.
Question 120: Which one of the following clinical features in a patient with bacterial meningitis carries the highest risk of poor neurological outcome?
- A. Delay in antibiotic administration of more than 3 hours after presentation
- B. Presence of focal neurological signs at presentation
- C. Glasgow Coma Scale score of less than 11 on admission (Correct Answer)
- D. Seizures occurring within the first 24 hours of presentation
- E. CSF white cell count of less than 1000 cells/μL
Explanation: ***Glasgow Coma Scale score of less than 11 on admission***- A **low admission GCS** is the single most powerful independent predictor of **mortality** and long-term **neurological sequelae** in bacterial meningitis.- It reflects severe cerebral dysfunction from **cerebral edema**, raised intracranial pressure, or encephalitis, with mortality rates reaching up to 40%.*Delay in antibiotic administration of more than 3 hours after presentation*- While **early antibiotics** are critical, a delay usually becomes a significant predictor of severe poor outcome when it exceeds **6 hours**.- Although detrimental, it is considered a secondary risk factor compared to the baseline **neurological status** at presentation.*Presence of focal neurological signs at presentation*- These signs indicate localized brain damage such as **arteritis**, **infarction**, or abscess formation but are less sensitive predictors of overall outcome than global consciousness.- Focal deficits are often associated with specific complications rather than being the primary driver of **overall mortality**.*Seizures occurring within the first 24 hours of presentation*- Early **seizures** are common in the acute phase of meningitis but often resolve once the **underlying infection** is treated.- While they represent cortical irritation, they do not correlate as strongly with permanent **neurological disability** as a low GCS score.*CSF white cell count of less than 1000 cells/μL*- A **low CSF pleocytosis** is a poor prognostic sign, particularly in **Streptococcus pneumoniae** infections, as it suggests an overwhelmed immune response.- Despite being a marker of severity, it is less reliable than the **clinical GCS score** for assessing the immediate risk of a poor neurological outcome.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free